Anton Leshchenko

Senior Vice President of Growth at FARMOVS
  • Claim this Profile
Contact Information
us****@****om
(386) 825-5501
Location
Groningen, Groningen, Netherlands, NL
Languages
  • Russian -
  • English -
  • German -
  • Ukrainian Limited working proficiency
Skills

Topline Score

Topline score feature will be out soon.

Bio

Generated by
Topline AI

5.0

/5.0
/ Based on 2 ratings
  • (2)
  • (0)
  • (0)
  • (0)
  • (0)

Filter reviews by:

Dr.Larysa Varenikova MBA, PhD

I am lucky to know Mr. Leshchenko personally many years and can say he is a gem of a person - caring, highly intellectual, ethical, full of energy and ideas, an expert negotiator are just

Dr.Larysa Varenikova MBA, PhD

I am lucky to know Mr. Leshchenko personally many years and can say he is a gem of a person - caring, highly intellectual, ethical, full of energy and ideas, an expert negotiator are just

You need to have a working account to view this content.
Join now
You need to have a working account to view this content.
Join now

Credentials

  • Artificial Intelligence and Business Strategy
    LinkedIn
    Sep, 2023
    - Oct, 2024
  • Improving Your Listening Skills
    LinkedIn
    Sep, 2023
    - Oct, 2024
  • Ten Habits of Great Decision Makers
    LinkedIn
    Sep, 2023
    - Oct, 2024
  • Accelerating Your Career with Personal Branding
    LinkedIn
    Aug, 2023
    - Oct, 2024
  • Finding Your Leadership Purpose with Doug Conant
    LinkedIn
    Aug, 2023
    - Oct, 2024
  • Increase Your Flexible Thinking Skills
    LinkedIn
    Aug, 2023
    - Oct, 2024
  • Six Sigma: Green Belt
    LinkedIn
    Aug, 2023
    - Oct, 2024
  • Communicating with Executives
    LinkedIn
    Jul, 2023
    - Oct, 2024
  • Negotiation Skills
    LinkedIn
    Jul, 2023
    - Oct, 2024
  • Generative AI for Digital Marketers
    LinkedIn
    Jun, 2023
    - Oct, 2024
  • Public Speaking Foundations
    LinkedIn
    Jun, 2023
    - Oct, 2024
  • How to Sell on Value, Not Price
    LinkedIn
    May, 2023
    - Oct, 2024
  • Betty Liu on Career Success
    LinkedIn
    Apr, 2023
    - Oct, 2024
  • Cold Calling: The First Seven Seconds
    LinkedIn
    Apr, 2023
    - Oct, 2024
  • Create a Go-to-Market Plan
    LinkedIn
    Apr, 2023
    - Oct, 2024
  • How to Master Your Executive Presence
    LinkedIn
    Apr, 2023
    - Oct, 2024
  • How to Think Strategically
    LinkedIn
    Apr, 2023
    - Oct, 2024
  • Job Interviewing for Leaders and Managers
    LinkedIn
    Apr, 2023
    - Oct, 2024
  • Leadership Principles for Emerging Leaders with Bill George
    LinkedIn
    Apr, 2023
    - Oct, 2024
  • Leading with Fearless Mindfulness
    LinkedIn
    Apr, 2023
    - Oct, 2024
  • Relationship Building for Creative Leaders
    LinkedIn
    Apr, 2023
    - Oct, 2024
  • Social Media Marketing with Facebook and Twitter
    LinkedIn
    Apr, 2023
    - Oct, 2024
  • Guy Kawasaki on Turning Life Wisdom into Business Success
    LinkedIn
    Mar, 2023
    - Oct, 2024
  • How to Speak So People Want to Listen
    LinkedIn
    Mar, 2023
    - Oct, 2024
  • The 3-Minute Rule: Say Less to Get More
    LinkedIn
    Mar, 2023
    - Oct, 2024
  • Lean Six Sigma Green Belt (ICGB)
    Eil Lilly

Experience

  • FARMOVS
    • South Africa
    • Research Services
    • 1 - 100 Employee
    • Senior Vice President of Growth
      • Nov 2022 - Present

      - Growth strategy through European and Global accounts - Building EU base for the expansion - Focus on the 1st in human CTs for the BioTech and MedTech latest technologies - Promoting African Science and Pharma Conducting Phase I-III clinical trials in Africa at FARMOVS (www.farmovs.com) First in Patient Unit offers a number of benefits for both the CROs and the pharmaceutical industry. Firstly, the large population and diverse demographic in Africa provide a wide range of patient populations for clinical trials, allowing for more representative and diverse data. Additionally, the cost of conducting clinical trials in Africa is generally lower compared to developed countries, which can help to reduce costs for the CROs and pharmaceutical companies. Furthermore, FARMOVS First in Patient Unit is an experienced and reputable clinical research organization that has a dedicated team of experts and state-of-the-art facilities that ensure high-quality data collection and safety of the trial participants. The company has a long-standing reputation of providing high-quality services that meet international standards. In addition, conducting clinical trials in Africa may help to increase access to new treatments and therapies for patients in the region, and it may also help to increase the participation of African populations in global clinical trials. This can lead to more inclusive and diverse data that can benefit the global population. Show less

  • EIM CEE - Executive Interim Management
    • Slovakia
    • Business Consulting and Services
    • 1 - 100 Employee
    • Member of Board of Senior Advisors. Life Science ~ Medical Devices/Disposables
      • May 2022 - Present

      EIM delivers business breakthrough differently. - We provide senior Interim Executives from our nurtured knowledge Community. - We partner actively with our Clients and Executives throughout the assignment to unlock performance potential. - We give our best when Clients need rapid solutions, transformation or out-performing results, anywhere in the World. With a community of more than 30000 Executives we have successfully performed over 10000 assignments in the past 30 years. Worldwide. We are inventors of Executive Interim Management. Show less

  • Kyowa Kirin International plc.
    • United Kingdom
    • Pharmaceutical Manufacturing
    • 400 - 500 Employee
    • General Manager CEE Cluster
      • Nov 2020 - Aug 2022

      Cluster General Manager for Central and Easter Europe. Rare Disease Business Unit - Setting up CEE Cluster organization during COVID year (13 positions filled within 7 months) Providing leadership and management of the cross-functional team Commercial, Medical Affairs, Finance/Supply Chain, QA, Digital, Legal and Compliance). - Market Access strategy designed and completed for 2 rare disease products in all 7 markets (Czech, Slovakia, Romania, Slovenia, Hungary, Bulgaria, Croatia). - >360% delivery of the 2021 actual results vs 2020. - Business Case for the organic growth expansion to the new territories. - Active participation during AIFP for the new law on orphan drugs for Czech Republic. Show less

  • KYBORA
    • United States
    • Investment Banking
    • 1 - 100 Employee
    • Managing Director CEE, Russia/CIS, Africa
      • Mar 2020 - Nov 2020

      CEE and Emerging markets of Africa (MAGREB, SADEC, FWA), Ukraine, Moldova, Georgia and Russia/CIS, MENA Life Science, Biotech, Medical Disposables, Veterinary, Digital Medicine - M&A Buy-Side / Acquisition - M&A Sell-Side / Divestment - In Licensing - Out Licensing - Market entrance consultancy - Tailored customer based Projects CEE and Emerging markets of Africa (MAGREB, SADEC, FWA), Ukraine, Moldova, Georgia and Russia/CIS, MENA Life Science, Biotech, Medical Disposables, Veterinary, Digital Medicine - M&A Buy-Side / Acquisition - M&A Sell-Side / Divestment - In Licensing - Out Licensing - Market entrance consultancy - Tailored customer based Projects

  • Sothema
    • Morocco
    • Pharmaceutical Manufacturing
    • 400 - 500 Employee
    • Board Advisor. Global BD&L
      • Sep 2019 - Mar 2020

      Strategic and Operations Development • Board member role responsible for the Gap analysis and Global expansion of SOTHEMA • Extending plan to SADEC, Eastern and Central Europe, GCC/MENA, Asia • Strategic and Alliance Partnerships with Global Pharma leaders for In-, Out- license and contract manufacturing services. Global BD&L Strategic and Operations Development • Board member role responsible for the Gap analysis and Global expansion of SOTHEMA • Extending plan to SADEC, Eastern and Central Europe, GCC/MENA, Asia • Strategic and Alliance Partnerships with Global Pharma leaders for In-, Out- license and contract manufacturing services. Global BD&L

  • SLK - Stolichnaya Laboratornaya Kompania
    • Global Business Development and Commercial Strategy Executive Director
      • Apr 2017 - May 2019

      Privately own structure with the focus on Market Access and Regulatory channels in Customs Union within niche medical disposables and pharmaceuticals. Has its own R&D focusing on hemostatic solutions in liquid and gel forms, as well as onco line R&D. • One-stop solution for pharmaceutical, medical disposable and/or equipment manufacturer to enter CIS/CEE markets. Full package from Regulatory (CROs and MoH) to Reimbursement, Pricing and Tender Planning. • Extending geographies for importation for local manufacturers from Ukraine, Georgia, Moldova and Russia/CIS/CEE to Africa, MENA, LATCAM • Spearhead partnership projects in base and niche medical disposables and pharmaceuticals in CIS (Common Independent States). 3 exclusive contracts for Ukraine/CIS. 16 products registered in 14 months. • Establish group of affiliates with local distribution network and coordinate high-impact promotions for private and tender business to cover all Ukraine, Belarus, Kazakhstan. • Implemented and secured access and reimbursement of centralized Tenders covering 60% of the demand. • Board Member. Show less

  • Avacare Health Group
    • South Africa
    • Pharmaceutical Manufacturing
    • 100 - 200 Employee
    • CEO (Emerging Markets)
      • Jan 2013 - Mar 2017

      Most agile Pharma and Medical Disposable grass-rout Group in SADEC with the presence in FWA and Central Africa covering +27 markets in Africa providing fare access to medical disposables, Rx and niche OTC, as well as services. • Launched holding structure from scratch to expand Avacare Group into international/global business operations in core lines such as Medical Disposables, Pharmaceuticals, and Orthopedics. • Instituted fully-fledged affiliates in CIS, and subsequently in Eastern Europe (e.g. Ukraine, Georgia, Uzbekistan). • Successfully forged partnerships in Ukraine, Kazakhstan, Belarus, Georgia, Azerbaijan, Moldova, and Armenia. • OEM management and API sourcing for Africa, MENA, Ukraine, Moldova, Georgia/CIS, CEE • Full Regulatory (CROs, direct to MoH) and Operations management process set up • Pricing, Reimbursement and Access Strategy Show less

  • Aspen Global Incorporated - Mauritius
    • Mauritius
    • Pharmaceutical Manufacturing
    • 100 - 200 Employee
    • Commercial Manager and Alliance Lead (IROKO Deal)
      • Jan 2009 - Dec 2012

      Aspen is the largest pharmaceutical company listed on the South African stock exchange as well as one of the top 20 companies listed on this exchange. Established in February 2008 to facilitate the internationalization of the Aspen Group, Aspen Global is the holding company for more than 60 subsidiaries and the intellectual property owner of Aspen’s entire internationally traded portfolio. Aspen Global’s portfolio comprises more than 90 products with 4,500 trademarks. Aspen Global is also responsible for sourcing and managing more than 3,500 stock keeping units from over 75 manufacturing sites around the world and supplying to more than 150 countries internationally. • Masterminded and executed distribution strategy for 24 markets in LATAM and CARICAM within 2 years. • Cultivated and maintained relationships with key distributors and affiliates’ commercial heads, as well as two partner companies, Iroko Holdings and Coreveo. • Successfully appointed as Board member for both Aspen and two partner companies. • Championed full-scope project management for Iroko deal encompassing more than 46 countries. • Solicited, negotiated, and secured distribution contract with 12 distributors globally, and propelled sales in key markets by 12%+ annually. • Structured innovative marketing/promotional strategy for products in Oncology and Cardiovascular lines. • Applied dynamic leadership talents toward directing, coaching, and motivating personnel across Regulatory, Financial, Supply Chain and Demand management functional areas. Show less

  • Eli Lilly
    • Regional Sales Manager, Eastern Siberia (sales assignment)
      • Jan 2008 - Jan 2009

      Sales assignment (Talent Development Program)• Steadily advanced through a series of promotions based on proven performance, dedication, loyalty, and revenue contributions. • Developed, mentored, motivated, and empowered team of eight medical representatives and affiliate portfolio comprising Endo, CNS, Oncology and Retail (Cialis) products. • Controlled and expanded region representing 28% of territory in Russia and 10% of affiliate sales plan. • Reversed declining sales trend to boost cumulative growth by 8% over 12 months.• Successfully positioned Cialis and retail team to achieve double-digit growth in one year. Show less

    • Senior Brand Manager CNS Portfolio
      • Feb 2005 - Jan 2008

      • Aligned, mobilized, and directed four marketers, led co-marketing activities with Boheringer Ingelheim, and engaged high-guild opinion leaders in Psychiatry and Neurology of CIS. • Contrived advocacy group support strategy and held Six Sigma Green Belt consulting roles for two projects. • Launched new antidepressant and Attention Deficit and Hyper Activity blockbusters in CIS/Russia• Shepherded anti-crisis cross-functional team following Zyprexa’s exclusion from Federal Reimbursement List and led Action Roadmap on getting back to the list. • Fueled sales in private and other non-reimbursed channels through generation and execution of a detailed action plan. Show less

    • New Products Planning Manager
      • Mar 2004 - Feb 2005

      • Provided influential marketing leadership for new pharmaceuticals from discovery through product decision and preparation for commercial success. • Planned, coordinated, and effectively orchestrated launch of new antidepressant (Cymbalta) in Russia, Ukraine and Kazakhstan. • Forged partnership with Boehringer Ingelheim to promote Duloxetine in CIS and set up NPP (New Product Planning) process with Russian affiliate and CIS.

    • Finance and Business Analyst
      • Oct 2002 - Mar 2004

      • Helmed P&L analysis and optimization by supervising complete spectrum of financial functions spanning budgeting, forecasting, business planning, financial metrics analysis, EVA, corporate finance affiliate metrics analysis, and risk management. • Implemented cross-functional process for business planning cycle which improved efficiency and quality of regional submissions.

Education

  • Schiller International University
    MBA, International Business
    2001 - 2002
  • Friends University
    BBA, Business Administration, Marketing
    1995 - 1997

Community

You need to have a working account to view this content. Click here to join now